专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP0998295A1 THE PROCESS FOR THE PREPARATION OF A STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION OF ANTI INFECTIVE AGENT/AGENTS AND MICRO ORGANISMS AS ACTIVE INGREDIENTS 失效
标题翻译：用于生产固体制剂稳定的药物组合物，抗感染物质和微生物作为活性成分
公开(公告)号：EP0998295A1
公开(公告)日：2000-05-10
申请号：EP98909680.5
申请日：1998-04-03
申请人： Cadila Pharmaceuticals (E.A.) Ltd. , Modi, Rajiv Indravadan , Bansal, Yatish Kumar , Khamar, Bakulesh Mafatlal
发明人： MODI, Rajiv, Indravadan,Kaka-Ba, , BANSAL, Yatish, Kumar , KHAMAR, Bakulesh, Mafatlal
IPC分类号： A61K35/74
CPC分类号： A61K35/747 , A61K9/0095 , A61K9/209 , A61K9/4808 , A61K9/5084 , A61K35/744 , A61K36/064 , A61K45/06 , A61K2300/00
摘要： Micro organisms are useful in management of diseases including diarrhoea and gastro intestinal diseases like pseudomembranous colitis, megacolon etc. They are also useful in prevention of gastro intestinal disturbances and diseases caused by anti-infective agents like ampicillin, amoxycillin, cloxacillin, clauvanic acid, cefuroxime axetel, cephalixin, erythromycin etc. For prevention micro organisms are to be taken along with anti infective agents. When micro organisms are combined with anti-infective agents for ease of administration and improving compliance and therapeutic effect, the combination is not found to be stable at room temperature as micro organisms are sensitive to anti-infective agents and are destroyed by effect of anti-infective agent in composition. The present invention relates to the process of preparing a stable fixed dose composition of anti-infective agent with micro organism as active ingredient. The process includes preparation of various dosage forms for oral route like capsule, tablet and liquid formulation. The process comprises of providing an appropriate barrier by way of selected coating procedure to one of the active ingredients in such a way that micro organisms are not affected by anti-infective agents. This results in a stable composition. By using an appropriate coating technique composition is made to remain stable over a period of 3-36 months at ambient/room temperature. The ratio of micro organism to anti-infective agents in a composition can be 1:2 to 1:25 by weight. The ratio of 1:5 by weight is found to be optimal for the purpose. The amount of coating is dependent on the type of coating technique, dosage form i.e. capsule, tablet or liquid and desired self life. The micro organisms of the composition were found to be active after variable time period. They also provided therapeutic effect and eliminated gastro intestinal disturbances associated with anti-infective agents when evaluated in humans.

2. 发明公开

EP1490103A2 PROCESS FOR MANUFACTURING PHARMACEUTICAL COMPOSITION COMPRISES OF MYCOBACTERIUM W IN THE TREATMENT OF ASTHAMA(OBSTRUCTIVE LUNG DISEASE) 有权
标题翻译： METHOD FOR PRODUCING分枝杆菌W的药物组合物，治疗哮喘（慢性阻塞性肺疾病）
公开(公告)号：EP1490103A2
公开(公告)日：2004-12-29
申请号：EP03706802.0
申请日：2003-03-11
申请人： Modi, Rajiv Indravadan , Khamar, Bakulesh Mafatlal
发明人： Modi, Rajiv Indravadan , Khamar, Bakulesh Mafatlal
IPC分类号： A61K39/04 , A61K39/39 , A61P11/06
CPC分类号： A61K35/74 , A61K39/04
摘要： The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).

3. 发明公开

EP1663998A2 PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM FORM I 审中-公开
标题翻译：用于生产氯沙坦CALIUM FORM我
公开(公告)号：EP1663998A2
公开(公告)日：2006-06-07
申请号：EP04769282.7
申请日：2004-09-04
申请人： Khamar, Bakulesh Mafatlal , Modl, Indravadan Ambalal
发明人： KHAMAR, Bakulesh M., 201 "Ashadha" , MODL, Indravadan A., Ltd."Cadila Corporate Campus" , MADHUSUDANA, Rao , Cadila Pharmaceuticals Ltd. , RADHA (Achanatha), Cadila Pharmaceuticals Ltd. , RAJAPPA, Murali, Cadila Pharmaceuticals Ltd.
IPC分类号： C07D257/04
CPC分类号： C07D403/10
摘要： The present invention relates to a novel method for preparing trityl losartan and losartan potassium form I.

4. 发明公开

EP1296680A2 THE METHOD OF TREATING DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS INFECTION 审中-公开
标题翻译：耐药结核分枝杆菌感染的治疗方法
公开(公告)号：EP1296680A2
公开(公告)日：2003-04-02
申请号：EP01943723.5
申请日：2001-06-26
申请人： Khamar, Bakulesh Mafatlal
发明人： Khamar, Bakulesh Mafatlal
IPC分类号： A61K31/43 , A61K45/00
CPC分类号： A61K31/43 , A61K31/4409 , A61K2300/00
摘要： Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least tow first line anti-tuberculous drugs such as INH and rifampicin. Frequently, such MDR strains show resistance to all commonly used first-line agents i.e INH, rifampicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression on inhA or by mutations that lower the enzyme's affinity to NADH. Mutations in katG, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in NADH dehydrogenase (Ndh) of the respiratory chain. Increases expression of AhpC has been suggested as another mechanism of INH resistance in mycobacteria. The present invention provides method of treating drug resistance for Mycobacterium tuberculosis infection. According to present invention, a method is provided to employ penicillin with INH. This reduces the MIC of INH and makes resistant organisms sensitive. The level of penicillins required for reversal of INH resistance is known to be achieved and maintained by therapeutic doses of penicillins.
摘要翻译：对抗结核药物的多重耐药性对治疗结核病构成威胁。这些菌株对至少一线抗结核药物如INH和利福平耐药。通常，这种MDR菌株对所有常用的一线药物即INH，利福平，链霉素，乙胺丁醇和吡嗪酰胺显示出抗性。异烟肼是应用最广泛的抗结核药物。对异烟肼的耐药性可以通过增加inhA的表达或降低酶对NADH的亲和力的突变来发生。编码过氧化氢酶过氧化物酶的katG突变是最常见的抗性来源。另一种异烟肼耐药机制是由呼吸链NADH脱氢酶（Ndh）缺陷引起的。增加AhpC的表达已被认为是分枝杆菌中INH抗性的另一种机制。本发明提供了治疗结核分枝杆菌感染的药物抗性的方法。根据本发明，提供了一种使用青霉素和INH的方法。这降低了INH的MIC并使抗性生物体敏感。已知通过治疗剂量的青霉素实现并保持逆转INH抗性所需的青霉素水平。

5. 发明公开

EP1494749A2 PROCESS FOR PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIRETROVIRAL PROTEASE INHIBITOR WITH IMPROVED BIOAVAILABILITY 有权
标题翻译：一种用于生产抗逆转录病毒ONE蛋白酶抑制剂含有提高的生物利用率的药物组合物
公开(公告)号：EP1494749A2
公开(公告)日：2005-01-12
申请号：EP03710082.3
申请日：2003-04-04
申请人： Khamar, Bakulesh Mafatlal , Modi, Indravadan
发明人： Khamar, Bakulesh
IPC分类号： A61N1/00
CPC分类号： A61K31/635 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/505 , A61K2300/00
摘要： The present invention provides process for manufacturing antiretroviral protease inhibitor (saquinavir, indinavir, nelfinavir,lopinavir,amprenavir) with improved bioavailability by incorporating Piperine. The quantity of Piperine required for this purpose ranges up to 30 mgm per dosage form to be administered. The pharmaceutical compositions incorporating piperine may be prepared in the form of liquid, powder, capsule or tablet or any other desired dosage form. The improved bioavailability of the drug is helpful in reducing the amount of the drug to be consumed as well as no. and or frequency of dosage form to be consumed. This helps in improving compliance of patient.

6. 发明公开

EP1478391A1 METHOD OF PROVIDING PROPHYLAXIS FOR TUBERCULOSIS IN HIV POSITIVE INDIVIDUALS 审中-公开
标题翻译：程序对肺结核的艾滋病病毒感染者的预防
公开(公告)号：EP1478391A1
公开(公告)日：2004-11-24
申请号：EP03701636.7
申请日：2003-01-27
申请人： Khamar, Bakulesh Mafatlal , Modi, Rajiv Indravadan
发明人： Khamar, Bakulesh Mafatlal
IPC分类号： A61K39/04 , A61K39/39 , A61P31/06 , A61P35/00
CPC分类号： A61K39/04
摘要： Present invention relates to the method providing prophylaxis for tuberculosis in HIV positive individuals. According to present invention, vaccine made from 'Mycobacterium w' (Mw) is found to be useful in providing prophylaxis against tuberculosis in HIV positive individuals.

7. 发明授权

EP1137407B1 OPHTHALMIC FORMULATION COMPRISING A BETA BLOCKER AND CARBOPOL 有权
标题翻译： β受体阻滞剂和含有卡波姆眼科组合物
公开(公告)号：EP1137407B1
公开(公告)日：2004-02-18
申请号：EP99905124.6
申请日：1999-03-04
申请人： Khamar, Bakulesh Mafatlal
发明人： Khamar, Bakulesh Mafatlal
IPC分类号： A61K31/13 , A61K47/00 , A61K31/78 , A61P27/02
CPC分类号： A61K31/138 , A61K9/0048 , A61K31/216 , A61K31/4704 , A61K31/5355
摘要： Beta blockers are used as topical ophthalmic preparation for reducing Intra Ocular Pressure. B-blocker used for this purpose include timolol, levobunolol, carteolol, metipranalol. They reduce the aqueous production and thereby reduce I.O.P. They are commonly used as drops. Efficacy of topical B-blockers is dependent on concentration of drug in formulation. However, increasing the concentration of drug beyond approved dosage forms does not increase the efficacy significantly e.g. Timolol 0.5% has identical pressure lowering capacity as 1% Timolol. The attempts to improve pressure reduction efficiency of B-blockers has not met with success so far. The sustained release formulation of Timolol (Timolol XE) has resulted in amount of drug to achieve same therapeutic effect. However, none of the formulation has improved efficacy of drug for reducing I.O.P. The present invention relates to the process of manufacturing such formulation of B-blocker which improves its I.O.P lowering effect. The formulation so prepared is non-irritating and well tolerated. The process of manufacturing new formulation with improved efficacy involves use of carboprolol and preservative. The timolol 0.5% gel formulated using process was evaluated in normal as well as glaucomatous eyes. The reduction in I.O.P. is found to be approx. 15% more than found with drops in normal individuals. Similar findings are also observed in glaucomatous eyes.

8. 发明专利

GB2392620B Use of Mycobacterium w in the treatment of obstructive lung disease 未知
公开(公告)号：GB2392620B
公开(公告)日：2005-02-16
申请号：GB0400092
申请日：2003-03-11
申请人： MODI RAJIV INDRAVADAN , KHAMAR BAKULESH MAFATLAL , CADILA PHARMACEUTICALS LTD
发明人： KHAMAR BAKULESH MAFATLAL , MODI RAJIV INDRAVADAN
IPC分类号： A61K47/20 , A61K35/74 , A61K39/04 , A61K39/39 , A61P11/00 , A61P11/06
摘要： The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).

9. 发明专利

BR0303388A 未知
公开(公告)号：BR0303388A
公开(公告)日：2004-07-20
申请号：BR0303388
申请日：2003-03-11
申请人： RAJIV INDRAVADAN MODI , KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K47/20 , A61K35/74 , A61K39/04 , A61K39/39 , A61P11/00 , A61P11/06 , C12N9/48 , C12N1/20
摘要： The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).

10. 发明专利

AU2003208505A1 PROCESS FOR PREPARATION OF PHARMACEUTICAL COMPOSITION 未知
公开(公告)号：AU2003208505A1
公开(公告)日：2003-09-29
申请号：AU2003208505
申请日：2003-03-06
申请人： MODI RAJIV INDRAVADAN , DAVE BRIJESH , RAMANI CHANDIR CHIMANDAS , NAIK PRAFUL , KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K35/74 , A61P31/06
摘要： The invention relates to the method of treating tuberculosis comprises use of a microorganism Mycobacterium w for the treatment of tuberculosis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式